These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 33061865)
1. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. Parhofer KG; Chapman MJ; Nordestgaard BG Eur Heart J Suppl; 2020 Oct; 22(Suppl J):J21-J33. PubMed ID: 33061865 [TBL] [Abstract][Full Text] [Related]
2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
3. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Boden WE; Bhatt DL; Toth PP; Ray KK; Chapman MJ; Lüscher TF Eur Heart J; 2020 Jun; 41(24):2304-2312. PubMed ID: 31872245 [TBL] [Abstract][Full Text] [Related]
4. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132 [TBL] [Abstract][Full Text] [Related]
5. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Lawler PR; Kotrri G; Koh M; Goodman SG; Farkouh ME; Lee DS; Austin PC; Udell JA; Ko DT Eur Heart J; 2020 Jan; 41(1):86-94. PubMed ID: 31733058 [TBL] [Abstract][Full Text] [Related]
6. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Kedia AW; Lynch E Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247 [TBL] [Abstract][Full Text] [Related]
7. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM; Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373 [TBL] [Abstract][Full Text] [Related]
9. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. Bazarbashi N; Miller M Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. Picard F; Steg PG Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024 [TBL] [Abstract][Full Text] [Related]
11. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM; J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607 [TBL] [Abstract][Full Text] [Related]
12. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Orringer CE; Jacobson TA; Maki KC J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586 [TBL] [Abstract][Full Text] [Related]
13. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM; N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628 [TBL] [Abstract][Full Text] [Related]
15. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Nordestgaard BG Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957 [TBL] [Abstract][Full Text] [Related]
16. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. Picard F; Bhatt DL; Ducrocq G; Ohman EM; Goto S; Eagle KA; Wilson PWF; Smith SC; Elbez Y; Steg PG Int J Cardiol; 2021 Oct; 340():96-104. PubMed ID: 34450192 [TBL] [Abstract][Full Text] [Related]
17. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081 [TBL] [Abstract][Full Text] [Related]
18. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]